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We read with interest the timely review on the clinical evidence
for regression of liver ﬁbrosis [1]. We were surprised that in such
a review there was no mention of the validated quantitative
methods of histological assessment of ﬁbrosis. We feel that this
is a serious omission for reasons we detail below.
Traditional histological staging of ﬁbrosis is semi-quantitative
and assesses both ﬁbrosis and architectural changes in a series of
categories [2]. These categories are assigned numbers, which are
conventionally used for scoring, but there is no quantitative rela-
tion between them, i.e., stage 2 does not mean twice as much
ﬁbrosis as stage 1 [2]. More importantly, conventional histologi-
cal staging cannot sub-classify cirrhosis, where one-year mortal-
ity varies from 1 to 57% depending on the clinical stage. HVPG is
quantitative and is a proven valid surrogate marker of portal
hypertension that applies to advanced liver disease [3]. However,
what is needed is a quantitative measurement of ﬁbrosis that can
be used in any stage of liver disease.
We have already described and validated a method of liver
collagen quantiﬁcation as collagen proportionate area (CPA)
using computer-assisted digital analysis in picro-Sirius Red-
stained histological sections [4]. CPA correlated well with both
Ishak staging and HVPG, but was a better histological correlate
with HVPG than Ishak stage [4]. We subsequently showed that
CPA, at protocol 1-year biopsy post-liver transplantation for
HCV cirrhosis, was highly predictive of the clinical outcome
deﬁned as decompensation or liver-related death, and it was bet-
ter than both Ishak score and HVPG [5]. Furthermore, in Ishak
stages 5 and 6, CPA correlated with HVPG, but had a greater sen-
sitivity for distinguishing ‘‘early’’ from ‘‘late’’ severe ﬁbrosis/cir-
rhosis [6]. From a technical aspect, the same amount of tissue
is needed to measure CPA as it is to stage ﬁbrosis from a biopsy
[7] and there are no signiﬁcant differences between measure-
ments in the right and left liver lobe [8]. More importantly, CPA
measurement can be performed routinely, as the actual reading
takes 10 min.
Other groups have also independently evaluated morphomet-
ric analysis of ﬁbrosis. Notably, area of ﬁbrosis was a more sensi-
tive marker of ﬁbrosis regression than METAVIR stage in 38
patients with HCV and SVR who had paired liver biopsies, occur-
ring in 89% of patients as compared to 61%, respectively [9].
We believe that regression of ﬁbrosis cannot be adequately
assessed with traditional histological systems and that validated
methods that quantify ﬁbrosis should be applied. In therapeutic
trials this would ensure picking up even small beneﬁts in earlier
stages of disease and quantitative assessment would also meet
the increasing clinical and prognostic need of sub-classifying cir-
rhosis. Non-invasive ﬁbrosis markers as predictors of clinical out-
come should be validated, compared, and even used in
conjunction with quantitative ﬁbrosis measurements to maxi-Journal of Hepatology 2mize their utility. In the future, ﬁbrosis stages should be used
in conjunction with quantitative assessment such as CPA to
assess histological response.
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